CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK
|出版日||ページ情報||英文 169 Pages
|CountryFocus：英国の医療・規制・医療費償還制度の情勢 CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK|
|出版日: 2018年12月01日||ページ情報: 英文 169 Pages||
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the UK. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the UK. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.
The value of the UK pharmaceutical market increased from £13.2bn ($20.3bn) in 2010 to £19.6bn ($25.9bn) in 2017, at a compound annual growth rate (CAGR) of 5.9% in the terms of GBP and 3.5% in the terms of US$. The market is expected to reach £26.2bn ($30.9bn) in 2022. The increased usage of personalized medicines, incorporating digital technology into drug development and accelerating drug access pathway, high disease burden and rise in elderly population are the main driving factors of pharmaceutical market. In 2015, the medical device market in the UK was worth $17.8 billion, which increased to $19.1 billion in 2017 at a CAGR of 3.6%. It is expected to grow at a CAGR of 4.1% from $19.8 billion in 2018 to $26.3 billion in 2025. The main segments were in vitro diagnostics, ophthalmic devices, cardiovascular devices, wound care devices and orthopedic devices. The development in personalized or precision medicines, incorporation of genetic sequencing and personal genome data, is revolutionizing the approach medical practitioners and pharmaceutical industries are undertaking for the disease treatment.
The report provides information on the healthcare, regulatory, and reimbursement landscape in the UK, and includes -
This report will enhance your decision-making capability by allowing you to -